IDYA (IDEAYA Biosciences Inc) רווח למניה בארבעת הרבעונים האחרונים

The current EPS YoY TTM growth trend in the GURU.Markets terminal is illustrated by this chart, where the current level is -144.30. IDEAYA Biosciences (IDYA) price action depends on the outcomes of darovasertib trials and payments from Pfizer and GSK. The company's capital is formed through advances from pharma behemoths for oncology innovations, while the future value of assets is based on the ability to maintain pricing power for synthetic lethality therapies.

This indicator measures the dynamics of net income per share on a rolling annual basis, reflecting the efficiency of monetizing operating results. In the case of IDEAYA Biosciences (IDYA), this metric demonstrates the impact of investments from pharma behemoths on the development of targeted mutation therapies, while the current EPS YoY TTM growth rate allows for an assessment of the risk of false breakouts at historical lows.